Cardiff Oncology Inc
NASDAQ:CRDF
Cardiff Oncology Inc
NASDAQ:CRDF
Price:
3.46 USD
-1.7%
Market Closed
Updated:
May 7, 2024
Section:
Relative Value
The Relative Value of one
CRDF
stock under the Base Case scenario is
0.07
USD.
Compared to the current market price of 3.46 USD,
Cardiff Oncology Inc
is
Overvalued by 98%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CRDF
Relative Value
Base Case
0.07
USD
Overvaluation 98%
Valuation Multiples
Multiples Across Competitors
CRDF Competitors Multiples
Cardiff Oncology Inc Competitors
Cardiff Oncology Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Cardiff Oncology Inc
NASDAQ:CRDF
|
154.6m USD | 316.8 | -3.7 | -1.8 | -1.8 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
286.9B USD | 5.3 | 59.5 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
161B USD | 5.5 | 42.8 | 18.2 | 30 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
105.9B USD | 10.7 | 29.2 | 23.5 | 24.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.1B USD | 8.1 | 27.5 | 22.2 | 24.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.9B USD | 3 | 169.3 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.7B USD | 8.9 | -7.7 | -8.3 | -7.3 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.3 | 27.1 | 13.9 | 17.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.2 | 46 | 63.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
